RESUMO
PURPOSE OF REVIEW: The risk of incident atherosclerotic cardiovascular disease (ASCVD) in primary prevention is typically lower than in secondary prevention. However, there is a spectrum of risk among individuals undergoing primary prevention with the risk in some individuals approaching those of secondary prevention. We review the clinical conditions wherein the risk in primary prevention is similar to that observed in secondary prevention. RECENT FINDINGS: Among individuals without established ASCVD, coronary artery calcium (CAC) scores ≥ 300 AU are associated with ASCVD event rates similar to secondary prevention populations. CAC score ≥ 1,000 AU are associated with an ASCVD risk seen in very high-risk secondary prevention populations. Interpretation of these observations must however consider differences in the risk reduction strategies. Current guidelines dichotomize ASCVD prevention into primary and secondary prevention, but certain primary prevention patients have an ASCVD risk equivalent to that of secondary prevention populations. Identifying higher risk primary prevention populations will allow for better risk mitigation strategies.
Assuntos
Prevenção Primária , Prevenção Secundária , Humanos , Prevenção Secundária/métodos , Prevenção Primária/métodos , Aterosclerose/prevenção & controle , Fatores de Risco , Medição de Risco , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/epidemiologia , Doença da Artéria Coronariana/prevenção & controle , Doença da Artéria Coronariana/epidemiologiaRESUMO
PURPOSE OF REVIEW: This review examines the pathophysiological interactions between COVID-19 and heart failure, highlighting the exacerbation of heart failure in COVID-19 patients. It focuses on the complex mechanisms driving worse outcomes in these patients. RECENT FINDINGS: Patients with pre-existing heart failure experience more severe symptoms and higher mortality rates due to mechanisms such as cytokine storms, myocardial infarction, myocarditis, microvascular dysfunction, thrombosis, and stress cardiomyopathy. Elevated biomarkers like troponin and natriuretic peptides correlate with severe disease. Long-term cardiovascular risks for COVID-19 survivors include increased incidence of heart failure, non-ischemic cardiomyopathy, cardiac arrest, and cardiogenic shock. COVID-19 significantly impacts patients with pre-existing heart failure, leading to severe symptoms and higher mortality. Elevated cardiac biomarkers are indicators of severe disease. Acute and long-term cardiovascular complications are common, calling for ongoing research into targeted therapies and improved management strategies to better prevent, diagnose, and treat heart failure in the context of COVID-19.
RESUMO
Resumen La sarcoidosis es una enfermedad granulomatosa crónica relacionada frecuentemente con antígenos ambientales e infecciones. Sin embargo, no se ha logrado identificar una causa clara en todos los escenarios. Por su parte, la amiloidosis secundaria se caracteriza por el depósito de proteína amiloide AA en los diferentes tejidos, la cual se asocia a procesos inflamatorios crónicos. Es supremamente infrecuente coincidir con estas dos enfermedades ya que no existe una relación de causalidad directa. A continuación presentamos un caso de un paciente con hallazgos de esta rara asociación.
Abstract Sarcoidosis is a chronic granulomatous disease, frequently attributed to environmental antigens (organic and inorganic) and infections. However, it is quite common not to find a clear cause behind this pathology. Alternatively, secondary amyloidosis is characterized my Amyloid AA protein deposition in different tissues, which is associated with chronic inflammation. Nonetheless, it is extremely uncommon to find both sarcoidosis and secondary AA amyloidosis simultaneously provided that there is no a clear causality relationship between both. We present an interesting case of a patient with this uncommon duality.
RESUMO
Abstract: The transvenous implantable cardiac defibrillator (T-ICD) is currently considered the standard of care for prevention of sudden cardiac death in patients with structural cardiac disease or channelopathies. However, the use of these devices is associated with a significant increase of short and long-term complications, mostly related to intravascular leads. The subcutaneous implantable cardiac defibrillator (S-ICD) is a novel alternative for high-risk patients susceptible to intravascular lead complications, with a similar efficacy as T-ICD. Multiple ongoing clinical trials involving the S-ICD are expected to provide additional information about safety, use and benefits in the clinical setting.
Resumen: El desfibrilador cardiaco implantable transvenoso (DCI-T) se considera actualmente el tratamiento estándar para la prevención de la muerte súbita cardiaca en pacientes con enfermedad cardiaca estructural o canalopatías. Sin embargo, el uso de estos dispositivos se asocia con un aumento significativo de complicaciones a corto y largo plazo, principalmente relacionadas con derivaciones intravasculares. El desfibrilador cardiaco implantable subcutáneo (DCI-S) es una alternativa novedosa para pacientes de alto riesgo susceptibles a complicaciones intravasculares, con una eficacia similar al DCI-T. Se espera que varios ensayos clínicos en curso que involucran al DCI-S brinden información adicional sobre seguridad, uso y beneficios en el entorno clínico.